


# Unique patients Excellent outcomes

The Edwards SAPIEN 3 Pulmonic Portfolio – where heart valve innovation and living life to the fullest meet



# Built on a proven platform and designed for durable performance

## Frame design


Cobalt-chromium for high radial strength and circularity

## Outer sealing skirt

Designed to minimize paravalvular leak

## Bovine pericardial tissue

Backed by 40+ years of tissue innovation



SAPIEN 3 valve



With pulmonic patients living longer and having higher expectations for their health and quality of life, lifetime management is increasingly important.

**That's why valve choice matters,** and the Edwards SAPIEN 3 pulmonic portfolio delivers.



Over **6,300 patients** treated with a SAPIEN valve in the pulmonic position in the United States alone.

# Proven technology that extends SAPIEN 3 valve benefits to more patients


The Alterra adaptive prestant—accurate, secure placement for an expanded group of patients

## Open cell geometry

Allows for distal placement without compromising flow to the branch pulmonary arteries

## Nitinol frame

Delivers continuous wall apposition



## Flared apices

Designed for migration resistance

## Landing zone

With radiopaque markers for placement of the SAPIEN 3 valve

SAPIEN 3 valve with the Alterra adaptive prestant



Engineered to be minimally invasive and potentially reduce reinterventions—so patients can maximize their time away from surgery and keep moving forward.



# Excellent clinical outcomes, patient after patient

	SAPIEN 3 valve at 5 years <sup>1*</sup>	SAPIEN 3 valve with the Alterra adaptive present at 2 years <sup>2†</sup>
Mortality	<b>0%</b> (n=42)	<b>2%</b> (n=118)
≤ Mild pulmonary regurgitation	<b>95%</b> (n=40)	<b>92%</b> (n=93)
Freedom from reintervention	<b>98%</b> (n=41)	<b>98%</b> (n=118)

 Demonstrated to minimize complications that impact the need for reintervention

\*In patients with dysfunctional right ventricular outflow tract (RVOT) conduit or surgical bioprosthetic valve.

†In patients with native or surgically-repaired right ventricular outflow tract.

#### References:

1. Aboulhosn, Jamil Five-year Results from the COMPASSION S3 Trial Treatment of Patients with a Dysfunctional RVOT Conduit or Previously Implanted Pulmonic Valve with the SAPIEN 3 Transcatheter Heart Valve; Presented at PICS 2024, San Diego, CA
2. Dimas, V. Vivian Transcatheter Pulmonary Valve Implantation with the Alterra Adaptive Present, SAPIEN 3 Transcatheter Heart Valve and Pulmonary Delivery System: Two-year Pooled Outcomes of the ALTERRA trial; Presented at PICS 2024, San Diego, CA


# Delivery systems that offer controlled, predictable, and precise positioning

Ready to adapt and adjust based on patient needs



## Alterra Delivery System

**Recapture and reposition** with ergonomic control, smooth tracking, and a system developed specifically for the Alterra adaptive pre-sent.



## Pulmonic Delivery System

**Covered system** designed to track through complex anatomies and deliver the SAPIEN 3 valve into the Alterra adaptive pre-sent.



## Edwards Commander Delivery System

**Dual articulation** designed for precise positioning and deployment of the SAPIEN 3 valve.

## Additional products:

*Atrioseptostomy Catheters for Creation of Atrial Septal Defects*





Miller Balloon  
Atrioseptostomy  
Catheter



Fogarty® Dilation  
Atrioseptostomy  
Catheter




> Deliver excellent outcomes, potentially delay reintervention, and **improve quality of life** for more of your pulmonic patients.



> Lifesaving devices for the smallest of patients



Explore the trusted Edwards SAPIEN 3 pulmonic portfolio



Please see pocket for Important Safety Information.

**CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.**

Edwards, Edwards Lifesciences, the stylized E logo, Alterra, COMPASSION, COMPASSION S3, Edwards Commander, Edwards SAPIEN, Edwards SAPIEN 3, Fogarty, Miller, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. All rights reserved. PP--US-10127 v2.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com



# Important Safety Information

## Edwards SAPIEN 3 Transcatheter Heart Valve System – Pulmonic

**Indications:** The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System with Edwards Commander Delivery System is indicated for use in the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional right ventricular outflow tract (RVOT) conduit or surgical bioprosthetic valve in the pulmonic position with  $\geq$  moderate regurgitation and/or a mean RVOT gradient of  $\geq$  35 mmHg.

**Contraindications:** The Edwards SAPIEN 3 THV System with Edwards Commander Delivery System is contraindicated in patients who cannot tolerate an anticoagulation/antiplatelet regimen or who have active bacterial endocarditis or other active infections.

**Warnings:** The devices are designed, intended, and distributed for single use only. **Do not resterilize or reuse the devices.** There are no data to support the sterility, nonpyrogenicity, and functionality of the devices after reprocessing. Correct sizing of the valve into the non-compliant RVOT conduit or failing bioprosthesis (landing zone) is essential to minimize risks. Too small of a valve may result in paravalvular leak, migration, or valve embolization; whereas too large of a valve may result in residual gradient (patient-prosthesis mismatch) or RVOT rupture. Accelerated deterioration of the valve may occur in patients with an altered calcium metabolism. Assessment for coronary compression risk prior to valve implantation is essential to prevent the risk of severe patient harm. The physician must verify correct orientation of the valve prior to its implantation; the inflow (outer skirt end) of the valve should be oriented toward the proximal end (handle) of the delivery system to prevent the risk of severe patient harm. Prior to delivery, the valve must remain hydrated at all times and cannot be exposed to solutions other than its shipping storage solution and sterile physiologic rinsing solution. Valve leaflets mishandled or damaged during any part of the procedure will require replacement of the valve. Patients with pre-existing bioprostheses should be carefully assessed prior to implantation of the valve to ensure proper valve positioning and deployment. Do not use the valve if the tamper-evident seal is broken, the storage solution does not completely cover the valve, the temperature indicator has been activated, the valve is damaged, or the expiration date has elapsed. Do not mishandle the delivery system or use it if the packaging or any components are not sterile, have been opened or are damaged (e.g., kinked or stretched), or the expiration date has elapsed. Use of excessive contrast media may lead to renal failure. Measure the patient's creatinine level prior to the procedure. Contrast media usage should be monitored. Patient injury could occur if the delivery system is not un-flexed prior to removal. Care should be exercised in patients with hypersensitivities to cobalt, nickel, chromium, molybdenum, titanium, manganese, silicon, and/or polymeric materials. The procedure should be conducted under fluoroscopic guidance. Some fluoroscopically guided procedures are associated with a risk of radiation injury to the skin. These injuries may be painful, disfiguring, and long-lasting. It is recommended that all prosthetic heart valve recipients be prophylactically treated for endocarditis to minimize the possibility of prosthetic valve infection. Valve recipients should be maintained on anticoagulant/antiplatelet therapy, except when contraindicated, as determined by their physician. This device has not been tested for use without anticoagulation. Do not add or apply antibiotics to the storage solution, rinse solutions or to the valve.

**Precautions:** Long-term durability has not been established for the valve. Regular medical follow-up is advised to evaluate valve performance. Glutaraldehyde may cause irritation of the skin, eyes, nose and throat. Avoid prolonged or repeated exposure to, or breathing of, the solution. Use only with adequate ventilation. If skin contact occurs, immediately flush the affected area with water; in the event of contact with eyes, seek immediate medical attention. For more information about glutaraldehyde exposure, refer to the Material Safety Data Sheet available from Edwards Lifesciences. To maintain proper valve leaflet coaptation, do not overinflate the deployment balloon. Appropriate antibiotic prophylaxis is recommended post-procedure in patients at risk for prosthetic valve infection and endocarditis. Patient venous anatomy should be evaluated to prevent the risk of access that would preclude the delivery and deployment of the device. Patient should be heparinized to maintain the ACT at  $\geq$  250 sec prior to introduction of the delivery system in order to prevent thrombosis. Safety and effectiveness have not been established for patients with the following characteristics/comorbidities: Blood dyscrasias defined as: leukopenia, acute anemia, thrombocytopenia, or history of bleeding diathesis or coagulopathy. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid™), or clopidogrel (Plavix™), or sensitivity to contrast media, which cannot be adequately premedicated. Positive urine or serum pregnancy test in female subjects of child-bearing potential. Residual mean gradient may be higher in a "THV-in-failing bioprosthesis" configuration than that observed following implantation of the valve inside a native annulus using the same size device. Patients with elevated mean gradient post procedure should be carefully followed. It is important that the manufacturer, model and size of the preexisting bioprosthetic valve be determined, so that the appropriate valve can be implanted and a prosthesis-patient mismatch be avoided. Additionally, pre-procedure imaging modalities must be employed to make as accurate a determination of the inner diameter as possible.

**Potential Adverse Events:** Potential risks associated with the anesthesia, interventional procedure and imaging include but are not limited to: death; stroke/transient ischemic attack; respiratory insufficiency or respiratory failure; cardiovascular or vascular injury, such as perforation or damage (dissection) of vessels, myocardium or valvular structures including rupture of the RVOT that may require intervention; pericardial effusion/cardiac tamponade; embolic event: air, calcific material, thrombus, device fragments; infection including incisional site infection, septicemia and endocarditis; myocardial infarction; renal insufficiency or renal failure; conduction system injury, arrhythmia, arteriovenous (AV) fistula; systemic or peripheral nerve injury, systemic or peripheral ischemia, pulmonary edema, pneumothorax, pleural effusion, atelectasis; blood loss requiring transfusion; anemia; radiation injury; electrolyte imbalance; hypertension or hypotension; allergic reaction to anesthesia, contrast media, antithrombotic therapy, device materials; hematoma or ecchymosis, syncope, pain, exercise intolerance or weakness, inflammation; angina; fever; cardiac failure. Potential risks associated with the valve, delivery system and/or accessories include, but may not be limited to, the following: cardiac arrest; cardiogenic shock; coronary flow obstruction/transvalvular flow disturbance, device thrombosis requiring intervention; injury to tricuspid valve; device embolization requiring intervention; device acute migration or malposition requiring intervention; endocarditis; hemolysis / hemolytic anemia; THV dysfunction resulting in pulmonary valve symptoms; mechanical failure of delivery system, and/or accessories; emergent and non-emergent re-intervention; dyspnea.

## Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestant

**Indications:** The Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestant is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement.

**Contraindications:** The Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestant is contraindicated in patients who cannot tolerate an anticoagulation/antiplatelet regimen or who have active bacterial endocarditis or other active infections.

# Important Safety Information (cont.)

**Warnings:** The devices are designed, intended, and distributed for single use only. **Do not resterilize or reuse the devices.** There are no data to support the sterility, nonpyrogenicity, and functionality of the devices after reprocessing. The physician must verify correct orientation of the valve prior to its implantation; the inflow (outer skirt end) of the valve should be oriented towards the proximal end (handle) of the delivery system to prevent the risk of severe patient harm. Prior to delivery, the valve must remain hydrated at all times and cannot be exposed to solutions other than its shipping storage solution and sterile physiologic rinsing solution. Valve leaflets mishandled or damaged during any part of the procedure will require replacement of the valve. Do not use the valve if the tamper evident seal is broken, the storage solution does not completely cover the valve, the temperature indicator has been activated, the valve is damaged, or the expiration date has elapsed. Do not mishandle the delivery system or use it if the packaging or any components are not sterile, have been opened or are damaged (e.g., kinked or stretched), or the expiration date has elapsed. Do not add or apply antibiotics to the storage solution, rinse solutions or to the valve.

**Precautions:** Long-term durability has not been established for the device. Regular medical follow-up is advised to evaluate device performance. Patients with hypersensitivities to cobalt, nickel, chromium, molybdenum, titanium, manganese, silicon, and/or polymeric materials may have an allergic reaction to these materials. Accelerated deterioration of the valve may occur in patients with an altered calcium metabolism. Assessment for coronary compression risk prior to implantation is recommended. Patient venous anatomy should be evaluated to prevent the risk of access that would preclude the delivery and deployment of the device. Use of excessive contrast media may lead to renal failure. Measure the patient's creatinine level prior to the procedure. Contrast media usage should be monitored. Fluoroscopically guided procedures are associated with a risk of radiation injury to the skin. Patient radiation dose should be monitored during the procedure. Glutaraldehyde may cause irritation of the skin, eyes, nose and throat. Avoid prolonged or repeated exposure to, or breathing of, the solution. Use only with adequate ventilation. If skin contact occurs, immediately flush the affected area with water; in the event of contact with eyes, seek immediate medical attention. For more information about glutaraldehyde exposure, refer to the Material Safety Data Sheet available from Edwards Lifesciences. Patient should be heparinized to maintain the ACT at  $\geq 250$  sec prior to introduction of the delivery system in order to prevent thrombosis. To maintain proper valve leaflet coaptation, do not overinflate the deployment balloon. Device recipients should be maintained on anticoagulant/antiplatelet therapy, except when contraindicated, as determined by their physician. This device has not been tested for use without antiplatelet therapy. It is recommended that all device recipients be prophylactically treated for endocarditis to minimize the possibility of prosthetic valve infection. Correct sizing of the presten into the RVOT is essential to minimize risks such as paravalvular leak, migration, embolization, and/or RVOT rupture. If a presten fracture is detected with significant loss in valve functionality, reintervention should be considered. Safety and effectiveness have not been established for patients with the following characteristics/comorbidities: blood dyscrasias defined as: leukopenia, acute anemia, thrombocytopenia, or history of bleeding diathesis or coagulopathy; a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid™), or clopidogrel (Plavix™), or sensitivity to contrast media, which cannot be adequately premedicated; positive urine or serum pregnancy test in female patients of childbearing potential.

**Potential Adverse Events:** Potential risks associated with the anesthesia, interventional procedure, and imaging include but are not limited to death; stroke/transient ischemic attack; respiratory insufficiency or respiratory failure; cardiovascular or vascular injury, such as perforation or damage (dissection) of vessels, myocardium, or valvular structures, including rupture of the RVOT that may require intervention; pericardial effusion/cardiac tamponade; cardiac failure; embolic event: air, calcific material, thrombus, device fragments; infection, including incisional site infection, septicemia, and endocarditis; myocardial infarction; renal insufficiency or renal failure; conduction system injury; arrhythmia; deep vein thrombosis; arteriovenous (AV) fistula; systemic or peripheral nerve injury; systemic or peripheral ischemia; pulmonary edema; pneumothorax; pleural effusion; dyspnea; atelectasis; dislodgement of previously implanted devices (i.e. pacing lead); blood loss requiring transfusion; anemia; radiation injury; electrolyte imbalance; hypertension or hypotension; allergic reaction to anesthesia, contrast media, antithrombotic therapy, device materials; hematoma or ecchymosis; syncope; pain; exercise intolerance or weakness; inflammation; angina; fever. Potential risks, that may or may not require intervention, associated with the valve, presten, delivery system, and/or accessories include, but may not be limited to, the following: cardiac arrest; cardiogenic shock; coronary flow obstruction/transvalvular flow disturbance; device thrombosis; injury to tricuspid valve; device fracture; device embolization; device acute migration or malposition; endocarditis; chest pain/discomfort; hemolysis/ hemolytic anemia; device penetration/perforation into surrounding vasculature; device dysfunction (regurgitation and/or stenosis); aortic root distortion; embolic events: device fragments; mechanical failure of delivery system, and/or accessories.

## **Edwards Crimper**

**Indications:** The Edwards crimper is indicated for use in preparing the Edwards SAPIEN 3 transcatheter heart valve for implantation.

**Contraindications:** There are no known contraindications.

**Warnings:** The device is designed, intended, and distributed for single use only. **Do not resterilize or reuse the device.** There are no data to support the sterility, nonpyrogenicity, and functionality of the device after reprocessing. Do not mishandle the device. Do not use the device if the packaging or any components are not sterile, have been opened or damaged, or the expiration date has elapsed.

**Precautions:** For special considerations associated with the use of the Edwards crimper prior to THV implantation, refer to the THV Instructions for Use.

**Potential Adverse Events:** There are no known potential adverse events associated with the Edwards crimper.

**CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.**

Edwards, Edwards Lifesciences, the stylized E logo, Alterra, Edwards Commander, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. PP--US-10127 v2.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com



Edwards